Production (Stage)
ArriVent BioPharma, Inc.
AVBP
$20.40
-$0.23-1.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 54.80% | -14.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.94% | -2.17% | |||
| Operating Income | -12.94% | 2.17% | |||
| Income Before Tax | -212.06% | -0.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -212.06% | -0.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -212.06% | -0.34% | |||
| EBIT | -12.94% | 2.17% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -210.36% | 0.07% | |||
| Normalized Basic EPS | -17.54% | 0.05% | |||
| EPS Diluted | -210.36% | 0.07% | |||
| Normalized Diluted EPS | -17.54% | 0.05% | |||
| Average Basic Shares Outstanding | 0.54% | 0.40% | |||
| Average Diluted Shares Outstanding | 0.54% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||